- Home
- INSM vs TEF Comparison
INSM vs TEF Comparison
Compare INSM & TEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- TEF
- Stock Information
- Founded
- INSM 1988
- TEF 1924
- Country
- INSM United States
- TEF Spain
- Employees
- INSM N/A
- TEF N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- TEF Telecommunications Equipment
- Sector
- INSM Health Care
- TEF Telecommunications
- Exchange
- INSM Nasdaq
- TEF Nasdaq
- Market Cap
- INSM 26.0B
- TEF 30.3B
- IPO Year
- INSM 2000
- TEF 1987
- Fundamental
- Price
- INSM $145.10
- TEF $5.35
- Analyst Decision
- INSM Strong Buy
- TEF
- Analyst Count
- INSM 19
- TEF 0
- Target Price
- INSM $142.38
- TEF N/A
- AVG Volume (30 Days)
- INSM 3.0M
- TEF 625.8K
- Earning Date
- INSM 10-30-2025
- TEF 11-06-2025
- Dividend Yield
- INSM N/A
- TEF 4.42%
- EPS Growth
- INSM N/A
- TEF N/A
- EPS
- INSM N/A
- TEF N/A
- Revenue
- INSM $398,105,000.00
- TEF $48,779,800,354.00
- Revenue This Year
- INSM $32.47
- TEF N/A
- Revenue Next Year
- INSM $126.03
- TEF $0.04
- P/E Ratio
- INSM N/A
- TEF N/A
- Revenue Growth
- INSM 21.15
- TEF 3.10
- 52 Week Low
- INSM $60.40
- TEF $3.89
- 52 Week High
- INSM $146.84
- TEF $5.72
- Technical
- Relative Strength Index (RSI)
- INSM 79.86
- TEF 47.43
- Support Level
- INSM $128.02
- TEF $5.29
- Resistance Level
- INSM $146.84
- TEF $5.38
- Average True Range (ATR)
- INSM 3.66
- TEF 0.06
- MACD
- INSM 0.71
- TEF -0.03
- Stochastic Oscillator
- INSM 91.65
- TEF 18.48
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About TEF Telefonica SA
Telefonica operates mobile and fixed networks in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.